|
業務類別
|
Biotechnology |
|
業務概覽
|
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain,and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need. |
| 公司地址
| 677 N. Washington Boulevard, Sarasota, FL, USA, 34236 |
| 電話號碼
| +1 718 400-9031 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.silopharma.com |
| 員工數量
| 3 |
| Mr. Eric Weisblum |
Chairman of the Board, Chief Executive Officer and President |
美元 350.00K |
27/03/2026 |
| Mr. Daniel E. Ryweck |
Chief Financial Officer and Principal Accounting Officer |
美元 60.00K |
27/03/2026 |
|
|
| Dr. Kevin Munoz |
Independent Director |
27/03/2026 |
| Mr. Eric Weisblum |
Chairman of the Board, Chief Executive Officer and President |
27/03/2026 |
| Dr. Jeff Pavell, M.D. |
Independent Director |
27/03/2026 |
| Mr. Wayne D. Linsley |
Independent Director |
27/03/2026 |
|
|
|
|
